logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9409856 B1

PDFFull Text
Date of Patent:
Aug. 09, 2016

Filed:

Jun. 08, 2015

Estrogen receptor ligands and methods of use thereof

Applicant:

Gtx, Inc., Memphis, TN (US);

Inventors:

James T. Dalton, Ann Arbor, MI (US);

Christina Herring, Oakland, TN (US);

Duane D. Miller, Collierville, TN (US);

Seoung-Soo Hong, Collierville, TN (US);

Yali He, Germantown, TN (US);

Michael L. Mohler, Memphis, TN (US);

Ramesh Narayanan, Cordova, TN (US);

Zhongzhi Wu, Collierville, TN (US);

Assignee:

Gtx, Inc., Memphis, TN (US);

Attorneys:

Mark S. Cohen

Pearl Cohen

Zedek Latzer Baratz LLP

Primary Examiner:

Shailendra Kumar

Int. Cl.
CPC ...
C07C 215/82 (2006.01); C07C 235/56 (2006.01); C07D 295/135 (2006.01); C07C 233/75 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/4453 (2006.01); C07D 221/12 (2006.01); C07D 211/06 (2006.01); C07D 295/155 (2006.01); C07C 255/58 (2006.01); C07C 311/21 (2006.01); C07C 311/29 (2006.01); C07C 235/16 (2006.01); C07C 235/24 (2006.01); C07C 235/38 (2006.01); C07C 251/48 (2006.01);
U.S. Cl.
CPC ...
C07C 215/82 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/4453 (2013.01); C07C 233/75 (2013.01); C07C 235/16 (2013.01); C07C 235/24 (2013.01); C07C 235/38 (2013.01); C07C 235/56 (2013.01); C07C 251/48 (2013.01); C07C 255/58 (2013.01); C07C 311/21 (2013.01); C07C 311/29 (2013.01); C07D 211/06 (2013.01); C07D 221/12 (2013.01); C07D 295/135 (2013.01); C07D 295/155 (2013.01); C07C 2101/14 (2013.01);
Abstract

The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.

Find Patent Forward Citations

Loading…